



Published on *British Columbia Drug and Poison Information Centre (BC DPIC)* (<http://www.dpic.org>)

[Home](#) > [Drug Product Listings](#) > [Hydrocodone + phenylephrine + pyrilamine + ammonium chloride](#) > [Printer-friendly PDF](#)

Hydrocodone + phenylephrine + pyrilamine + ammonium chloride

Trade Name:

Hycomine Syrup

Manufacturer/Distributor:

Bristol-Myers Squibb

www.bmscanada.ca 1-800-267-0005

Classification:

Narcotic

ATC Class:

R05DA20 - Narcotic cough suppressant combinations

Status:

discontinued

Date Marketed in Canada (yyyy/mm/dd):

2011/05/11

Presentation:

Oral Liquid: 1 mg/mL hydrocodone + other ingredients. DIN: 01916564

Comments:

The manufacturer has reviewed the commercial potential of this product and has decided to discontinue the manufacture and sale of Hycomine syrup, 500 mL container size.

Keywords: hydrocodone
drug discontinuation

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the [Health Canada Drug Product Database](#)

Status:

<Any>

?

Search Terms:

Apply

[A](#) (37) | [B](#) (20) | [C](#) (24) | [D](#) (37) | [E](#) (40) | [F](#) (12) | [G](#) (11) | [H](#) (9) | [I](#) (24) | [K](#) (1) | [L](#) (26) | [M](#) (12) | [N](#) (7) | [O](#) (12) | [P](#) (28) | [R](#) (14) | [S](#) (27) | [T](#) (33) | [U](#) (4) | [V](#) (13) | [W](#) (2)

| Z (4)

<u>Generic Name</u>	<u>Common Trade Name(s)</u>	<u>Classification</u>	<u>Date Marketed in Canada (yyyy/mm/dd)</u>
<u>Doravirine + Lamivudine + Tenofovir</u>	Delstrigo	Antiviral agent	2018/12/15
<u>Doripenem</u>	Doribax	Antibacterial agent	2009/09
<u>Doxepin</u>	Silenor	Hypnotic	2012/01/08
<u>Dronabinol</u>	Marinol	Antiemetic	2012/02/24
<u>Dronedarone</u>	Multaq	Antiarrhythmic agent	2009/08/14
<u>Drospirenone + estetrol</u>	Nextstellis	Oral contraceptive	2021/06/15
<u>Drotrecogin alfa</u>	Xigris	Antithrombotic profibrinolytic anti-inflammatory enzyme	2011/10/25
<u>Dulaglutide</u>	Trulicity	Antihyperglycemic agent	2016/01/08
<u>Dupilumab</u>	Dupixent	Skin and mucous membrane agent	2017/11/30
<u>Dutasteride + tamsulosin</u>	Jalyn	Alpha-1 blocker + 5-Alpha reductase inhibitor	2012/02/03
<u>Eculizumab</u>	Soliris	Humanized monoclonal antibody	2009/06/29
<u>Edaravone</u>	Radicava	Treatment for amyotrophic lateral sclerosis	2019/10/29
<u>Edoxaban</u>	Lixiana	Anticoagulant	2017/01
<u>Elagolix</u>	Orilissa	Gonadotropin releasing hormone receptor antagonist	2018/10/31
<u>Elbasvir + grazoprevir</u>	Zepatier	Antiviral agent	2016/02/02
<u>Elexacaftor + tezacaftor + ivacaftor</u>	Trikafta	Cystic fibrosis transmembrane conductance regulator correctors	2021/06/22
<u>Eltrombopag</u>	Revolade	Thrombopoietin receptor antagonist	2011/04/04
<u>Eluxadoline</u>	Viberzi	Miscellaneous GI drug	2017/05
<u>Eluxadoline</u>	Viberzi	Miscellaneous GI drugs	2017/04/24
<u>Elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide</u>	Genvoya	Antiretroviral agents	2016/02/03

<u>Generic Name</u>	<u>Common Trade Name(s)</u>	<u>Classification</u>	<u>Date Marketed in Canada (yyyy/mm/dd)</u>
<u>Elvitegravir + Cobicistat + Emtricitabine + Tenofovir disoproxil fumarate</u>	Stribild	Antiretroviral agent	2012/12/20
<u>Empagliflozin</u>	Jardiance	Sodium-glucose contransporter 2 (SGLT2) inhibitor	2015/08/11
<u>Empagliflozin + linagliptin</u>	Glyxambi	Antidiabetic agent	2016/12/15
<u>Empagliflozin + metformin</u>	Synjardy	Oral blood glucose lowering agents	2017/09/18
<u>Emtricitabine + tenofovir</u>	Descovy	Antiretroviral agent	2016/06/03
<u>Enasidenib</u>	IDHIFA	Antineoplastic agent / IDH2 Inhibitor	2019/02/27
<u>Entrectinib</u>	Rozlytrek	Antineoplastic agent	
<u>Enzalutamide</u>	Xtandi	Antineoplastic agent	2013/06/07
<u>Eplerenone</u>	Inspra	Aldosterone antagonist	2009/02/26
<u>Eptinezumab</u>	Vyepti	Prevention of migraine; calcitonin gene-related peptide binding antibody	2021/01/11
<u>Erdafitinib</u>	Balversa	Protein kinase inhibitor	2019/12/09
<u>Erenumab</u>	Aimovig	Anti-calcitonin gene-related peptide receptor	2018/08/01
<u>Eribulin</u>	Halaven	Antineoplastic agent	2012/03/10
<u>Ertugliflozin</u>	Steglatro	Sodium-glucose co- transporter 2 (SGLT2) inhibitor	2018/05/23
<u>Ertugliflozin + metformin</u>	Segluromet	Oral blood glucose lowering agents	2018/05/30
<u>Ertugliflozin + sitagliptin</u>	Steglujan	Oral blood glucose lowering agents	2018/05/22

[« first](#) [previous](#) [1](#) [2](#) [3](#)

[4](#) [5](#) [6](#) [7](#) [8](#) [9](#)

? [next](#) ? [last](#) »

We are grateful to all the First Nations who have cared for and nurtured the lands and waters around us for all time, including the x?m??k??y??m (Musqueam), Sk?wx?wu?7mesh U?xwumixw (Squamish Nation), and s?l?ílw?ta? (Tsleil-Waututh Nation) on whose unceded

and ancestral territory our centre is located.

© 2024 BC Drug and Poison Information Centre

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is *not* meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the **full terms and conditions** below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

Terms and Conditions

Source URL (retrieved on 2025-06-09 20:41): <http://www.dpic.org/druglisting/hydrocodone-phenylephrine-pyrilamine-ammonium-chloride>